Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2010 December;52(4) > Panminerva Medica 2010 December;52(4):339-43

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEW  IMAGING AND FOCAL THERAPY IN PROSTATE AND KIDNEY CANCER PART II: FOCUS ON KIDNEY 

Panminerva Medica 2010 December;52(4):339-43

Copyright © 2010 EDIZIONI MINERVA MEDICA

lingua: Inglese

Glucocorticoid induced risk of fractures

Maruotti N., Corrado A., Cantatore F. P.

Departement of Rheumatology, University of Foggia Medical School, Foggia, Italy


PDF


In recent years studies have emphasized the importance of glucocorticoid-induced osteoporosis as the second most common form of osteoporosis after postmenopausal osteoporosis. Several studies have underlined that glucocorticoids are responsible for decreasing bone mineral density and increasing bone fragility, resulting in a large increase in fracture risk. This review wants to provide a background regarding the fracture risk of patients exposed to glucocorticoid treatment, considering the fracture risk as the most appropriate parameter to valuate glucocorticoid-induced osteoporosis. In fact, glucocorticoid treatment induces bone loss and increases fracture risk above all affecting trabecular bone, probably through an alteration in bone turnover and microarchitectural changes responsible for an early increased fracture risk which is primary influenced by dose and duration of treatment, body mass index, age and female gender.

inizio pagina